Get the Stockscreener App
225.28
1.50%
-3.43
After Hours:
225.28
Ascendis Pharma A S stock is traded at $225.28, with a volume of 444.32K.
It is down -1.50% in the last 24 hours and down -1.73% over the past month.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
See More
Previous Close:
$228.71
Open:
$229.06
24h Volume:
444.32K
Relative Volume:
0.64
Market Cap:
$13.92B
Revenue:
$823.12M
Net Income/Loss:
$-253.97M
P/E Ratio:
-53.67
EPS:
-4.1973
Net Cash Flow:
$52.82M
1W Performance:
+1.44%
1M Performance:
-1.73%
6M Performance:
+13.92%
1Y Performance:
+31.94%
1-Day Range:
$223.79
$230.24
1-Week Range:
$216.22
$231.78
52-Week Range:
$150.89
$250.74
Ascendis Pharma A S Stock (ASND) Company Profile
Compare ASND vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
225.28 | 14.13B | 823.12M | -253.97M | 52.82M | -4.1973 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-25 | Initiated | Raymond James | Strong Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| May-05-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-16-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | UBS | Buy |
| Sep-05-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-25-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Initiated | Stifel | Buy |
| Dec-20-23 | Initiated | Jefferies | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Neutral |
| Apr-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-04-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-03-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Aug-30-22 | Resumed | Berenberg | Buy |
| Mar-28-22 | Resumed | Wedbush | Outperform |
| Mar-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-14-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-06-22 | Initiated | Cowen | Market Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-20-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-30-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-11-21 | Resumed | Stifel | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Mar-20-20 | Initiated | Oppenheimer | Outperform |
| Oct-11-19 | Initiated | Morgan Stanley | Overweight |
| Mar-25-19 | Initiated | Evercore ISI | Outperform |
| Jan-24-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-19 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-18 | Initiated | Stifel | Buy |
| Apr-02-18 | Reiterated | Leerink Partners | Mkt Perform |
| May-11-17 | Initiated | JP Morgan | Overweight |
| Mar-09-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Feb-09-17 | Initiated | Credit Suisse | Outperform |
| Sep-26-16 | Initiated | Wedbush | Outperform |
View All
Ascendis Pharma A S Stock (ASND) Latest News
BofA raises Ascendis Pharma stock price target on Yuviwel pricing - Investing.com
MSN Money - MSN
ASND Price Today: Ascendis Pharma A/S Stock Price, Quote & Chart | MEXC - MEXC
Ascendis will post quarterly results before markets open May 7 - Stock Titan
Net debt of Ascendis Pharma A/S – SWB:A710 - TradingView
Price to earnings ratio of Ascendis Pharma A/S – SWB:A710 - TradingView
Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ascendis Pharma A/S (NASDAQ:ASND) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Breakeven Is Near for Ascendis Pharma A/S (NASDAQ:ASND) - 富途牛牛
Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Uptick And Ongoing Losses - simplywall.st
Ascendis Pharma A/S (ASND): Billionaire Joe Edelman Is Bullish on This Stock - Yahoo Finance
Ascendis Pharma A/S expected to post earnings of 28 cents a shareEarnings Preview - TradingView
Ascendis Pharma A/S (ASND) Stock Analysis: Unpacking a 29.97% Potential Upside for Investors - DirectorsTalk Interviews
Calamos Advisors LLC Has $3.48 Million Holdings in Ascendis Pharma A/S $ASND - MarketBeat
Ascendis Pharma rises amid takeover speculation - MSN
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech - MSN
Ascendis Pharma gains amid takeover speculation - MSN
Morgan Stanley Upgrades Ascendis Pharma A (ASND) - MSN
Latham & Watkins Advises Ascendis Pharma on Nasdaq Ordinary Share Listing - Latham & Watkins LLP
Ascendis Pharma slides as investors digest share-structure switch and convertible-note redemption - Quiver Quantitative
Ascendis Pharma Updates ISIN for Nasdaq-Listed Ordinary Shares - The Globe and Mail
Ascendis Pharma AS (MEX:ASNDN) Stock PDF (Updated: 2026/04/27) - GuruFocus
European ADRs Edge Higher As BHP Rallies And Nokia Drops - Finimize
Ascendis Pharma Announces Commencement of Trading of Its Ordinary Shares on Nasdaq - Moomoo
Ascendis Pharma A/S (ASND) Stock Report: A Promising Biotech with 20.95% Potential Upside - DirectorsTalk Interviews
Ascendis Pharma Completes ADS-to-Ordinary Share Conversion and Begins Direct Nasdaq Trading - TipRanks
Ascendis Pharma A/S(NasdaqGS: ASND) dropped from NASDAQ Composite Index - marketscreener.com
How YUVIWEL’s Orphan Exclusivity and U.S. Launch Will Impact Ascendis Pharma (ASND) Investors - Sahm
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Concentra Group Holdings Parent, Inc. (CON) - The Globe and Mail
Ascendis Pharma Share Conversion Reshapes Access And Liquidity On Nasdaq - Sahm
Why Ascendis Pharma Shares Are Slumping Despite Upgrade - TipRanks
Employee warrant grants at Ascendis Pharma (NASDAQ: ASND) - Stock Titan
Ascendis Pharma Issues New Employee Warrants as Part of Long-Term Incentive Program - TipRanks
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity - FinancialContent
How Investors May Respond To Ascendis Pharma (ASND) Achondroplasia Combo Data And YUVIWEL Launch - Sahm
Ascendis Pharma (ASND) to List Ordinary Shares Directly on Nasdaq - Yahoo Finance
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq - Sahm
Assessing Ascendis Pharma (ASND) Valuation After New COACH Trial Data And YUVIWEL Orphan Drug Exclusivity - Yahoo Finance
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq - GlobeNewswire Inc.
Ascendis Pharma (NASDAQ: ASND) to swap ADSs for ordinary shares in Nasdaq direct listing - Stock Titan
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States - Yahoo Finance
Ascendis Pharma A/S (ASND) stock price, news, quote and history - Yahoo Finance Singapore
Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial - Yahoo Finance
Cantor Fitzgerald reiterates Ascendis Pharma stock rating at overweight - Investing.com
Ascendis Pharma closes warrant exercise window and increases share capital - Investing.com
Ascendis Pharma Trial Wins And Valuation Gap Draw Investor Attention - Yahoo Finance
Revolution, Ascendis Named Top Buyout Targets as Industry Awaits The Big One - BioSpace
Ascendis Pharma (ASND) CFO lists warrants, RSUs and shares - Stock Titan
Ascendis Pharma (ASND) Is Down 5.8% After New Two-Year YUVIWEL Achondroplasia Data Release – Has The Bull Case Changed? - Sahm
Avoro Capital Advisors LLC Has $1.02 Billion Stock Holdings in Ascendis Pharma A/S $ASND - Defense World
Ascendis Pharma (ASND) slides 5.4% as post-FDA-approval enthusiasm fades and traders take profits - Quiver Quantitative
Ascendis Pharma A S Stock (ASND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):